L-ficolin levels in Chagas patients and controls.

<p>The statistical distribution is shown with median (line in the box), box indicating the 25–75 percentiles, whiskers the 5–95 percentile and arithmetic mean (cross inside the box).</p

<i>FCN2</i> genotype frequencies (%) in Chagas patients and controls.

<p>In bold: genotypes with −<i>4 A/G</i> heterozygosity, whose summed frequencies differ between cardiac patients and controls. Gray-shadowed: genotypes <i>AGGA/GGAS</i> and <i>GGAS/GGAS</i> (homozygote for <i>A258S</i>), whose summed frequencies differ between cardiodigestive patients and indeterminate patients or controls (see text).</p>*<p><i>A258S</i> was investigated by sequencing in a subset of 135 controls. n number of individuals.</p

Distribution of L-ficolin levels based on age and clinical classification.

<p>(A) L-ficolin levels in Chagas patients and controls according to age (B) L-ficolin levels in Chagas patients and controls based on class of cardiac commitment. The statistical distribution is shown with median and interquartile range. One outlier (18880.7 ng/ml) was excluded for better visualization in the 45–59 group of patients.</p

Distribution of L-ficolin levels based on genotypic variant and disease stages.

<p>(A) L-ficolin levels in Chagas patients and controls by the presence of <i>258S</i> variant and (B) Distribution of L-ficolin levels in Chagas patients and controls by disease stages. The statistical distribution is shown with median and interquartile range. Closed dots: samples with −<i>4 A/G</i> genotype. Closed boxes: samples with −<i>4 A/G</i> and <i>258A/S</i> (<i>AGGA/GGAS</i> genotype) or <i>258S/S</i> homozygotes (<i>GGAS/GGAS</i> genotype).</p

Demographic and clinical parameters of chronic Chagas patients.

*<p>MBL levels were determined by ELISA and C-reactive protein (hs-CRP) by nephelometry as previously described <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0060237#pone.0060237-Luz1" target="_blank">[6]</a> n number of investigated samples; N.d. not determined.</p>&<p>some patients were unspecified.</p

Correlations between anti-CCP and patient’s age and age at disease onset.

<p>Anti-CCP correlated with the age of patients (A) and age at disease onset (C). Anti-CCP studied according to patient’s age (B) and age at disease onset (D).</p

Distribution of MBL levels in different <i>MBL2</i> genotypes.

<p>Serum MBL levels according to different genotypes of studied <i>MBL2</i> variants in RA patients (A) and relatives (B).</p

Clinical and demographic features of the RA patients, relatives and healthy controls.

<p>Anti-CCP: anti-cyclic citrullinated peptide antibody, (^a): Total of samples with available data are 154; (^b): Total samples with available data are 74.</p><p>NS: Not significant; NA: not available; ND: not determined. Values expressed in medians and interquartiles range.</p

Distribution of MBL levels in RA patients segregated by clinical parameters.

<p>Distribution of MBL levels according to presence of nodules (A), Secondary Sjögren’s syndrome (B), positivity for anti-CCP (C) and positivity for Rheumatoid factor (D).</p

Distribution of MBL levels in different <i>MBL2</i> haplotypes and diplotypes.

<p><i>MBL2</i> diplotypes were reconstructed from promoter variant −221X/Y and variants in exon1 (Codon 52+54+57, A/O) and divided into high MBL producers (<i>YA/YA</i>), intermediate (<i>YA/YO</i>, <i>XA/XA</i> and <i>XA/YA</i>) and low MBL producers (<i>YO/YO</i>, <i>XA/YO</i>). Serum MBL levels were segregated according to different <i>MBL2</i> diplotypes in patients and relatives (A), and different <i>MBL2 </i>secretor haplotypes in RA patients (B) and relatives (C).</p